C9075 HCPCS Level II code: Injection, casimersen, 10 mg
CMS terminated C9075: its last date of service was Sep 30, 2021. It stays here for looking up older claims; newer services need a current code.
Official description
C9075Injection, casimersen, 10 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with C9075 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Other medical items or services; Ambulatory surgical center (facility usage for surgical services)
- BETOS category
- Other drugs
- Coverage statute
- 1833(t)
- Added
- Jul 1, 2021
- Terminated after
- Sep 30, 2021
Where C9075 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9075Injection, casimersen, 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9075 still valid?
No. CMS terminated C9075; its last date of service was Sep 30, 2021. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9075?
CMS lists C9075’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9075
All C codesC9069Injection, belantamab mafodontin-blmf, 0.5 mgC9070Injection, tafasitamab-cxix, 2 mgC9071Injection, viltolarsen, 10 mgC9072Injection, immune globulin (asceniv), 500 mgC9073Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseC9074Injection, lumasiran, 0.5 mgC9076Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseC9077Injection, cabotegravir and rilpivirine, 2mg/3mgC9078Injection, trilaciclib, 1 mgC9079Injection, evinacumab-dgnb, 5 mgC9080Injection, melphalan flufenamide hydrochloride, 1 mgC9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose